Article2015

The $2.6 Billion Pill — Methodologic and Policy Considerations

319 citations0/0 files storedNew England Journal of Medicine

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Health Systems, Economic Evaluations, Quality of Life Pharmaceutical industry and healthcare

Abstract

Interview with Dr. Jerry Avorn on a new estimate of the cost of bringing a drug to market. (12:09)Download An industry-supported center claims that it costs companies $2.6 billion to develop a new drug. But we need a broader-based and more transparent reckoning of research-and-development costs to inform discussions about fostering innovation and paying for medications.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 319 citations exist upstream.

Cited by

2018Financial toxicity and implications for cancer care in the era of molecular and immune therapies 2017How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries 2018Outrageous prices of orphan drugs: a call for collaboration 2020Pricing of pharmaceuticals is becoming a major challenge for health systems 2016A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility 2015The Cost of Drug Development 2017How Much Longer Will We Put Up With $100,000 Cancer Drugs?2019Public sector financial support for late stage discovery of new drugs in the United States: cohort study

Imported from OpenAlex (CC0) — nothing here is generated.